Category Archives: Stem Cells

Hematopoietic stem cell transplantation (HSCT) from haploidentical donors is a viable option for patients lacking HLA-matched donors. Here we report the results of a prospective multicenter phase I/II trial of transplantation of TCR and CD19-depleted peripheral blood stem cells from haploidentical family donors after a reduced-intensity conditioning with fludarabine, thiotepa, and melphalan. Thirty pediatric and 30 adult patients with acute leukemia (n=43), myelodysplastic or myeloproliferative syndrome (n=6), multiple myeloma (n=1), solid tumors (n=6), and non-malignant disorders (n=4) were enrolled. TCR /CD19-depleted grafts prepared decentrally at six manufacturing sites contained a median of 12.1106CD34+cells/kg and 14.2103TCR+T-cells/kg. None of the patients developed grade lll/IV acute graft-versus-host disease (GVHD) and only six patients (10%) had grade II acute GVHD. With a median follow-up of 733 days 36/60 patients are alive. The cumulative incidence of non-relapse mortality at day 100, 1 and 2 years after HSCT was 5%, 15%, and 17% for all patients, respectively. Estimated probabilities of overall and disease-free survival at 2 years were 63% and 50%, respectively. Based on these promising results in a high-risk patient cohort, haploidentical HSCT using TCR/CD19-depleted grafts represents a viable treatment option.

Go here to see the original:
Results of a multicenter phase I/II trial of TCR and CD19-depleted haploidentical hematopoietic stem cell transplantation for adult and pediatric...

About stem cells

Stem cells are the foundation of development in plants, animals and humans. In humans, there are many different types of stem cells that come from different places in the body or are formed at different times in our lives. These include embryonic stem cells that exist only at the earliest stages of development and various types oftissue-specific(oradult)stem cells that appear during fetal development and remain in our bodies throughout life.Stem cells are defined by two characteristics:

Beyond these two things, though, stem cells differ a great deal in their behaviors and capabilities.

Embryonic stem cells arepluripotent, meaning they can generate all of the bodys cell types but cannot generate support structures like the placenta and umbilical cord.

Other cells aremultipotent,meaning they can generate a few different cell types, generally in a specific tissue or organ.

As the body develops and ages, the number and type of stem cells changes. Totipotent cells are no longer present after dividing into the cells that generate the placenta and umbilical cord. Pluripotent cells give rise to the specialized cells that make up the bodys organs and tissues. The stem cells that stay in your body throughout your life are tissue-specific, and there is evidence that these cells change as you age, too your skin stem cells at age 20 wont be exactly the same as your skin stem cells at age 80.

Learn more about different types of stem cellshere.

See the original post here:
Stem Cell Basics - A Closer Look at Stem Cells

Background

Differentiation of functional limbal stem cells (LSCs) from human pluripotent stem cells (hPSCs) is an important objective which can provide novel treatment solutions for patients suffering from limbal stem cell deficiency (LSCD). Yet, further characterization is needed to better evaluate their immunogenicity and regenerative potential before clinical applications.

Human PSCs were differentiated towards corneal fate and cryopreserved using a clinically applicable protocol. Resulting hPSC-LSC populations were examined at days 1011 and 2425 during differentiation as well as at passage 1 post-thaw. Expression of cornea-associated markers including PAX6, ABCG2, Np63, CK15, CK14, CK12 and ABCB5 as well as human leukocyte antigens (HLAs) was analyzed using immunofluorescence and flow cytometry. Wound healing properties of the post-thaw hPSC-LSCs were assessed via calcium imaging and scratch assay. Human and porcine tissue-derived cultured LSCs were used as controls for marker expression analysis and scratch assays at passage 1.

The day 2425 and post-thaw hPSC-LSCs displayed a similar marker profile with the tissue-derived LSCs, showing abundant expression of PAX6, Np63, CK15, CK14 and ABCB5 and low expression of ABCG2. In contrast, day 1011 hPSC-LSCs had lower expression of ABCB5 and Np63, but high expression of ABCG2. A small portion of the day 1011 cells coexpressed ABCG2 and ABCB5. The expression of class I HLAs increased during hPSC-LSCs differentiation and was uniform in post-thaw hPSC-LSCs, however the intensity was lower in comparison to tissue-derived LSCs. The calcium imaging revealed that the post-thaw hPSC-LSCs generated a robust response towards epithelial wound healing signaling mediator ATP. Further, scratch assay revealed that post-thaw hPSC-LSCs had higher wound healing capacityin comparison to tissue-derived LSCs.

Clinically relevant LSC-like cells can be efficiently differentiated from hPSCs. The post-thaw hPSC-LSCs possess functional potency in calcium responses towards injury associated signals and in wound closure. The developmental trajectory observed during hPSC-LSC differentiation, giving rise to ABCG2+ population and further to ABCB5+ and Np63+ cells with limbal characteristics, indicates hPSC-derived cells can be utilized as a valuable cell source for the treatment of patients afflicted corneal blindness due to LSCD.

Link:
Corneal epithelial differentiation of human pluripotent stem cells generates ABCB5+ and Np63+ cells with limbal cell characteristics and high wound...

Department Department of Histology and EmbryologyFaculty of MedicineDeadline 28 Feb 2022Start date Jully 2022Job type full-timeJob field Science and research

Medical Faculty of Masaryk University, Brno, Czech Republic, invites excellent scientists to apply for

Postdoc position in Bioinformatics in Stem Cell Neurobiology

Description:

The Department of Histology and Embryology is an educational and research workplace at the Medical Faculty of Masaryk University, Brno, the Czech Republic. The Department provides courses on all aspects of normal structure and development of human tissues and organs to students of General medicine and Dentistry. The Department is recognized as premier place in the country for research mainly focusing on human pluripotent stem cells, their biology, and applications in biomedicine.

The successful candidate should:

Specific criteria for this position:

The applicant shall submit:

MU offers the opportunity to get:

Anticipated start date:The position is available from July 2022

The submission deadline is28. February 2022

How to apply:

Please use the "E-Application" link below. After submitting your application, you will receive an automatic confirmation of acceptance via email. For more information, please contact Martina Vrblkov atvrablikova@med.muni.cz.

Areview of applications will commence immediately after the deadline. Short-listed candidates will be invited for interview within one month of the deadline.

Further information about:

More:
Postdoc Position in Bioinformatics in Stem Cell Neurobiology job with MASARYK UNIVERSITY | 276195 - Times Higher Education (THE)

MELVILLE, N.Y., Dec. 20, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the Company" or BioRestorative) (NASDAQ:BRTX), a life sciences company focused on adult stem cell-based therapies, today released the following year-end message.

As we reach the end of 2021, we are inspired by the many healthcare workers and biopharmaceutical companies that have worked to combat the COVID-19 pandemic. This year has been environmentally difficult, but we have seen incredible advancements in our sector which have reinforced the importance of our mission to become a clinical stage company. Since our emergence from Chapter 11 in 2020, we have sought to take positive steps at BioRestorative Therapies with the goal of making it a preeminent cell therapy company. During 2021, we achieved important transformational milestones, which created meaningful intrinsic value and advanced us toward our stated strategic goals.

In November of this year, we closed on a $23 million capital raise and concurrently listed our securities on the Nasdaq Capital Market. This is a very significant development as we are now fully funded to complete our Phase 2 trial for our lead clinical candidate, BRTX-100, for the treatment of chronic lumbar disc disease (CLDD.) During this process, we have attracted many new institutional fundamental investors as well as some retail investors. With that accomplished, I would like to briefly discuss the status of our programs and the opportunities that lie ahead of us.

BRTX-100 is our lead program for the treatment of CLDD, one of the leading causes of lower back pain. Our solution is a one-time injection of 40 million mesenchymal stem cells derived from a patients own bone marrow and expanded ex vivo before re-injection. Two things make us optimistic about this program. First, in connection with our IND filing, we referred the FDA to prior human clinical studies from different institutions that demonstrated the safety/feasibility of using mesenchymal stem cells to treat disc orders. This data not only enabled us to accelerate our clinical program and initiate a Phase 2 trial, but we believe it substantially reduces risk in offering compelling guidance on the use of cell-based interventions to treat lower back pain. Second, our manufacturing of BRTX-100 involves the use of low oxygen conditions, which ensures that the cells have enhanced survivability after introduction into the harsh avascular environment of the injured disc which has little or no blood flow. The benefits of this process are significant and are illustrated well in our recent Journal of Translational Medicine publication. Our approach is akin to transplant medicine in which specific cell types are used to replace the ones which have been lost to disease. We believe that transplanting targeted cells can offer a more attractive safety profile and potentially an improved clinical outcome. We remain optimistic that we will see significant positive clinical outcomes as we proceed with our clinical trial.

The most significant milestones we achieved in 2021 include:

Our 2022 objectives include the initiation of enrollment for our BRTX-100 clinical trial, the development of our overall product profiles via manufacturing and delivery system improvements, and the entering into of technology validation and enabling partnerships to accelerate our clinical timelines.

Some of the events and milestones that we hope to accomplish in 2022 include:

This is an exciting time to be part of the BioRestorative family. As we enter 2022 with a well-capitalized balance sheet to fully fund our Phase 2 trial, we look to accelerate our research and development pipeline. We do not take for granted that our technologies give us an opportunity to make a profound impact on the everyday lives of many people. We are grateful for the opportunity to validate such technologies; it is what we do and what we believe is the center of our core competencies.

Visit our website atwww.biorestorative.comfor more information about BioRestorative.

Thank you to the BioRestorative family for your loyalty and ongoing support.

I wish you and all those near and dear to you a wonderful Holiday Season and the very best for 2022 and beyond.

Very truly yours,

Lance AlstodtPresident, CEO and Chairman of the Board

About BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc. (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders:

Disc/Spine Program (brtxDISC): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a persons own) cultured mesenchymal stem cells collected from the patients bone marrow. We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders or as a complementary therapeutic to a surgical procedure. The BRTX-100 production process utilizes proprietary technology and involves collecting a patients bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patients damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. We have received authorization from the Food and Drug Administration to commence a Phase 2 clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease.

Metabolic Program (ThermoStem): We are developing a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in animals may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes.

FORWARD-LOOKING STATEMENTS

This letter contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including, without limitation, those set forth in the Company's latest Form 10-K filed with the Securities and Exchange Commission (SEC) and other filings made with the SEC. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this letter are made as of the date hereof and the Company undertakes no obligation to update such statements.

CONTACT:

Email: ir@biorestorative.com

Continue reading here:
BioRestorative Therapies, Inc. Releases Year-End Message - GlobeNewswire

For years, stem cells have been a sort of magic word thrown around as a potential solution for all sorts of challenges in biology and medicine. Certainly, the potential inherent in cells which retain their ability to differentiate into different tissues is nothing to scoff at, but acquiring these cells in a reliable way remains a challenge even decades later.

In order to grow cells in a laboratory setting, researchers rely on additives like fetal calf serum, which is extracted from the coagulated blood drawn from a fetal cow. Once undesired portions of the blood are removed, youre left with a serum which is pretty good at helping cells to grow. The whole process, however, is messy and difficult to duplicate precisely. As a result, we cant be certain that cell lines grown in this way are always the same, something which is necessary when reproducing experiments and is especially important if you want to manufacture lab-grown meat, an increasing area of interest. That problem might now be solved, and lab-grown meats might be on their way to your dinner table.

A recent paper by Ramiro Alberio from the School of Biosciences at the University of Nottingham, and colleagues, describes a new well-defined method for stem cell expansion which could open doors to mass manufacturing of animal tissues for human consumption. Their findings were published in the December issue of Stem Cells and Regeneration.

For industrial applications or food production where regulators require that all components are as defined as possible, current methods have a lot of problems, Alberio told SYFY WIRE. Moving to chemically defined conditions is an important prerequisite for making a product that will enter the food chain.

The team found that only a few key criteria were needed to successfully grow stem cell lines in a lab and, surprisingly, that the same setup was effective in cells from multiple animal species. As a result, one system can grow tissues from cows, pigs, and sheep. In fact, the same criteria also apply to human and mouse cells, providing an added benefit for researchers while were all chowing down on synth-steaks.

We were able to come up with a single unifying recipe for the key components needed by stem cells, Alberio said.

Because researchers are working with stem cells as opposed to muscle cells which have already differentiated theyre able to take a single sample and grow the various tissue types needed to replicate the meat you might find at the grocery store.

Muscle, fat, and connective tissues were all successfully grown in the lab, but this process offers meat with some assembly required. Scientists dont construct those cells into fully-fledged meat products in the lab. Instead, it would be up to consumer companies to take these cellular building blocks and put them together into something you could fry up at a barbecue.

Like your favorite chain restaurant, its important to be able to produce a universal end-user experience free from the guesswork usually associated with stem cell production. Especially as cultured meat products are likely going to be met with some skepticism from the consumer public, scientists want to ensure theyre delivering a product which can be trusted. One of the major benefits of this process is its ability to deliver the same product time after time for at least several years, and probably longer.

These cells are very stable in culture. Weve grown them for about three years, and they are still stable. I wouldnt be able to give a finite number of how many times we can expand these cells though, Alberio said. Over time, cells are likely to acquire chromosomal abnormalities simply because the number of mitotic divisions is so huge. Inevitably there will be aberrations that emerge.

Alberio clarified, however, that those mutations are rare. Over the course of three years, theyve seen very few, but he urged the importance of closely monitoring the cultures and handling them as well as possible to ensure their stability over time. Should a particular line become unstable, it would likely need to be scrapped and replaced with a new sample. One way to minimize mutations is to grow the cells in a low oxygen environment, which is one of the ways this lab differs from others around the world.

We use low oxygen for growing the cells. They grow at 5% oxygen rather than 20%. This helps prevent reactive oxygen species being released in the medium which can have a detrimental effect on the chromosomal integrity. Keeping the cells in the best possible conditions allows us to expand the lifespan considerably.

The unique laboratory setting has other benefits as well, benefits which stand to revolutionize the meat production industry if theyre implemented. Because they are grown in a carefully controlled environment, theres no need for the introduction of antibiotics which are prevalent in factory farming. Alberio also noted the potential positive impact on climate change. Cows are known for their tendency to release methane into the atmosphere which contributes to warming. Globally, livestock are responsible for 14.5 of all greenhouse gases, a number which could be drastically reduced through cultured meat production.

When this technology becomes more mature and streamlined, we should be able to produce meat with no methane emissions whatsoever. There would be some CO2 emissions, but methane would be eliminated from the process of meat production, Alberio said.

The team is now looking to enhance the process by moving from 2D cultures to 3D culture systems which would increase the total volume of tissues they can produce. Theyre also looking at producing cell lines from living animals rather than embryos and culturing cells from specific individuals and breeds.

All of which means that menus of the future might include options from particularly famous animals, well-known for their especially delicious tissues, all while theyre happily living their lives somewhere. Win-win for everyone.

Excerpt from:
Pork or beef? Stem cells pave the way for lab-grown meat - SYFY WIRE

BOSTON High cholesterol and inflammation are key drivers of heart disease, and an inflamed buildup of lipids can cut off the blood supply through a coronary artery to cause a heart attack. Because white blood cells, which usually defend against infection, trigger inflammation in these situations, a team led by scientists at Massachusetts General Hospital (MGH) recently studied aspects related to the cells production. The groups insights, which are published in Nature Cardiovascular Research, could lead to new strategies to protect cardiovascular health.

In patients with heart disease, white blood cells are more numerous, says senior author Matthias Nahrendorf, MD, PhD, an investigator in MGHs Center for Systems Biology and a professor of radiology at Harvard Medical School. Many of these cells can be found in a plaquethe buildup of fats, cholesterol, and other substances in a blood vesselwhere they arrive after being born in the bone marrow and migrating through the blood stream. But what leads to their increased bone marrow output is not clear.

Through experiments conducted in human bone marrow and mice, Nahrendorf and his colleagues found that high blood pressure, atherosclerosis, and the occurrence of a heart attack each can cause changes in the number of blood vessels in the bone marrow. These hallmarks of cardiovascular disease also changed the bone marrow vessels structure and function and affected their release of factors that regulate white blood cell production and migration.

As a consequence, more white blood cells were available in the body, and this increase, called leukocytosis, propels inflammation everywhere, including in the arteries and the heart, explains Nahrendorf. This study will allow us to now examine how to reduce white blood cell production to normal values, thereby cooling off inflamed plaques anywhere in the body.

Co-authors include MGHs David Rohde, MD, Katrien Vandoorne, PhD and others.

Funding for the study was provided by the National Heart, Lung, and Blood Institute grant P01HL142494.

This study provides strong evidence that cardiovascular disease affects the bone marrow vasculature and consequently blood stem cell activity, said Michelle Olive, Ph.D., program officer in the Division of Cardiovascular Sciences at the National Heart, Lung, and Blood Institute, part of the National Institutes of Health. This work sheds new light on the important role played by the vascular bone marrow niche and how inflammation occurs. It could lead to new targets and treatments for heart disease, the leading cause of death.

About the Massachusetts General Hospital

Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. TheMass General Research Instituteconducts the largest hospital-based research program in the nation, with annual research operations of more than $1 billion and comprises more than 9,500 researchers working across more than 30 institutes, centers and departments. In August 2021, Mass General was named #5 in theU.S. News & World Reportlist of "Americas Best Hospitals."

Bone marrow endothelial dysfunction promotes myeloid cell expansion in cardiovascular disease

23-Dec-2021

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

Go here to see the original:
Researchers uncover new details behind inflammation that promotes heart disease - EurekAlert

The Israeli firm Future Meat Technologies has raised a neat 308M ($347M) in the biggest financing round in the field of cultured meat to date. The company claims rapid progress in addressing scaling bottlenecks that slow the sectors growth.

A range of contributors pitched into the mammoth funding round including an undisclosed tech investor, ADM Ventures the venture capital arm of the US food processing giant Archer-Daniels-Midland and the UK-based Manta Ray Ventures.

Future Meat is one of many firms in the emerging cultured meat sector, where meat is grown directly from cultured animal cells. The goal is to reduce the amount of land, resources, and animal slaughter required to meet humanitys protein demand. Future Meat is developing a range of products including cell-based hamburgers, chicken breast, and kebab meat.

This financing consolidates Future Meats position as the leading player in the cultivated meat industry, just three years after our launch, said Yaakov Nahmias, founder and president of Future Meat, in a public statement.

In 2020, cultured meat firms globally raised 319m ($360M) six times more than in 2019. Future Meats 308M Series B round alone nearly matches this sum. With the cash in hand, Future Meat plans to build a large-scale production facility in the US in 2022. The firm is focusing on obtaining US approval of its cell-based chicken before it expands to other regions.

This year promises even more funding going to cultured meat companies. One example is Good Meat, the cultured meat arm of the US firm Eat Just, which has raised 236M ($267M) so far this year. Eat Justs cell-based chicken became the first cultured meat product to receive marketing approval last year when Singapore gave it the green light. Another Israeli cultured meat developer, Aleph Farms, raised 89M ($105M) in its own Series B round in July.

In Europe, meanwhile, multiple big rounds have been raised this year by the likes of Meatable, Gourmey, and Mosa Meat. And the Brazilian meat giant JBS acquired the Spanish cultured meat startup BioTech Foods in November.

Funding for cultivated meat companies through the end of [the third quarter of] 2021 was already up 184% compared to all of 2020, and this doesnt even take into account the $347M raised by Future Meat Technologies, said Carlotte Lucas, Corporate Engagement Manager at the Good Food Institute, a non-profit organization dedicated to accelerating research into meat alternatives.

A September article from The Counter voiced concerns over the economic performance of cultured meat technology; production plants will find it very difficult to compete at a large scale with traditional slaughterhouses. Reasons include the need for expensive serum to nourish the cells, and the requirement for costly cell growth facilities.

You can make a big plant, or you can make a clean plant, David Humbird, chemical engineer and author of a report on the cultured meat sector for the investment entity Open Philanthropy, told The Counter. So if you want to feed millions and millions of people, its got to be big. But if you want to do it with animal cells, its got to be clean. We need both, and you cant do that.

In November, Mosa Meat welcomed the analysis from The Counter in a detailed blog post, with the argument that scaling up the technology could be feasible with continued investments and innovation.

Its far too early to be certain if and when cultivated meat will be produced at industrial scales and affordable prices, noted Lucas. As weve seen with smartphones, solar panels and genome sequencing, many impactful technologies that now shape our lives were unimaginable before key scientific breakthroughs made them possible.

Cultivated meat companies and scientists have already successfully challenged many historical assumptions about animal cell culture, and we have far from exhausted the creativity of researchers in this field.

Nahmias disagreed with the criticism, saying that the calculations are based on stem cell approaches, which is different to Future Meats method. Instead of using stem cells or muscle cells as the basis for the meat, the company uses fibroblasts, which are the cells that make connective tissue such as scar tissue. These cells are more resilient than stem cells and can be grown in vats more easily.

Our proprietary media rejuvenation technology enables cell densities greater than 100 billion cells per liter, translating to production densities 10 times higher than the industrial standard, stated Nahmias.

According to Future Meats latest announcement, the company has already exceeded expectations in bringing down the cost of manufacturing its chicken meat. Each 110-gram chicken breast costs 1.50 ($1.70) to produce less than half of what it cost six months ago.

While 2020 saw soaring demand for meat alternatives, the last six months have seen stagnating consumer interest in plant-based meat products. In November, for example, Beyond Meats stock fell by 19% as its sales fell short of expectations. As cultured meat technology matures and enters the market, some analysts see cell-based meats outshining plant-based products in the coming years.

With everyone eating at home, Covid-19 created a unique atmosphere for incredible retail sales growth for plant-based foods, so its no surprise that the industry couldnt maintain that growth rate as the world started to open up, said Lucas. But if you take a step back and look at the overall trajectory of the industry, demand from consumers is continuing to grow.

I feel like the meat-alternative field is inherently limited, as most people still seek the real thing, said Nahmias. This is where cultured meat is fundamentally different from existing alternatives; we arent an alternative, we are the real thing.

23 December 2021: Article updated with comments from Future Meat Technologies

Cover image via Elena Resko

More:
Future Meat Lands 308M in Biggest-Ever Cultured Meat Investment - Labiotech.eu

CD8 T cells are a type of white blood cells that are essential for the immune system to fight infections and cancer.

DALLAS Dec. 17, 2021 What if the key to aging well lies in reprogramming immune system cells to strengthen them against infections and cancer? Researchers at UT Southwestern are working to find out.

Tuoqi Wu, Ph.D., Assistant Professor of Immunology

Tuoqi Wu, Ph.D., Assistant Professor in the Department of Immunology and in the Harold C. Simmons Comprehensive Cancer Center, studies aging in immune cells. His groundbreaking work at UT Southwestern was recently recognized with a grant from the Glenn Foundation for Medical Research and the American Federation for Aging Research, part of a $2.26 million mulifaceted grant program in support of biomedical research on aging.

Dr. Wu will investigate potential opportunities to improve immunity using strategies to reverse age-driven decline in CD8 T cell immunity. The results from this study could help develop novel interventions to improve immune surveillance against infections and cancer, diseases associated with increased frequency in the elderly, Dr. Wu said.

CD8 T cells are a type of white blood cells and are essential for the immune system to fight infections. As people age, these cells become less effective in controlling infections, and the risk of infection-related hospitalizations, deaths, and cancer increases. In addition, vaccines are less protective in the elderly because they work by activating the immune system.

The UT Southwestern scientists recently discovered a type of CD8 T cells, termed stem cell-like CD8 T cells, which have longer lifespans and are more effective in combating infections and cancer. In this study, they will evaluate strategies to reverse age-driven decline in CD8 T cell immunity by reprograming the aged CD8 T cells into stem cell-like CD8 T cells.

UT Southwestern is ranked as one of the nations top 25 hospitals for both cancer and geriatric care.

UT SouthwesternsHarold C. Simmons Comprehensive Cancer Center, the only National Cancer Institute-designated comprehensive cancer center in North Texas, includes five research and 12 clinical care programs with a focus on fostering groundbreaking translational research that can improve patient treatment, address cancer health disparities, and prevent cancer worldwide. In addition, the Centers education and training programs support and develop the next generation of cancer researchers and clinicians. The comprehensive designation and associated funding is designed to bolster the cancer centers research and to provide patients access to innovative clinical trials with promising new drugs. Simmons Cancer Center members currently have over $90 million in extramural cancer-focused research funding.

About UTSouthwestern Medical Center

UTSouthwestern, one of the premier academic medical centers in the nation, integrates pioneering biomedical research with exceptional clinical care and education. The institutions faculty has received six Nobel Prizes, and includes 25 members of the National Academy of Sciences, 16 members of the National Academy of Medicine, and 14 Howard Hughes Medical Institute Investigators. The full-time faculty of more than 2,800 is responsible for groundbreaking medical advances and is committed to translating science-driven research quickly to new clinical treatments. UTSouthwestern physicians provide care in about 80 specialties to more than 117,000 hospitalized patients, more than 360,000 emergency room cases, and oversee nearly 3 million outpatient visits a year.

View post:
UTSW working to reprogram cells to strengthen immunity in geriatric patients - UT Southwestern

DUBLIN--(BUSINESS WIRE)--The "Induced Pluripotent Stem Cell (iPSC) Market Share, Size, Trends, Industry Analysis Report By Application (Manufacturing, Academic Research, Drug Development & Discovery, Toxicity Screening, Regenerative Medicine); By Derived Cell; By Region, Segment & Forecast, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.

The global Induced Pluripotent Stem Cell (iPSC) market size is expected to reach $2,893.3 million by 2028

The ability to model human diseases in vitro as well as high-throughput screening has greatly propelled market growth. Companies have effectively overcome market hurdles faced in the recent past such as proper culturing and differentiation of derived cells at a commercial scale and have developed state-of-the-art manufacturing processes that can achieve scalability and can achieve stringent quality parameters. Such trends are propelling the overall industry growth.

Companies have also developed advanced platforms for Induced pluripotent stem cells that guarantee close connection with a host of in-house technologies that are useful in the proper definition of disease signatures as well as relationships between genetic mutations as well as that properly describe perturbation of specific molecular pathways. This has resulted in the creation of human translational models that are aiding better target identification of diseases that have high unmet medical needs.

Many companies have developed transfection kits, reprogramming vectors, differentiation media, live staining kits, immunocytochemistry, among others to aid the smooth workflow of iPSC production.

However, it has been observed in the recent past that the demand for cells for screening and other purposes is significant and that there are significant challenges that pose a significant hurdle in large-scale iPSC production and differentiation.

Heavy investment in R&D activities pertaining to the development and optimization of iPSC reprogramming process in order to achieve sufficient production is a key industry trend. In the recent past, companies focused more on hepatic, cardiac, pancreatic cells, among others.

However, with the advent of a number of new participants as well as advancements and breakthroughs achieved, it is anticipated that the application portfolio will further increase in the near future.

Industry participants operating in the industry are:

Key Topics Covered:

1. Introduction

2. Executive Summary

3. Research Methodology

4. iPSC Market Insights

4.1. iPSC - Industry Snapshot

4.2. iPSC Market Dynamics

4.2.1. Drivers and Opportunities

4.2.1.1. Increasing demand for body reconstruction procedures and tissue engineering

4.2.1.2. Rising Investments across the globe

4.2.2. Restraints and Challenges

4.2.2.1. Scalability Issues

4.3. Porter's Five Forces Analysis

4.4. PESTLE Analysis

4.5. iPSC Market Industry trends

4.6. COVID-19 Impact Analysis

5. Global iPSC Market, by Derived Cell

5.1. Key Findings

5.2. Introduction

5.3. Hepatocytes

5.4. Fibroblasts

5.5. Amniotic Cells

5.6. Cardiomyocytes

6. Global iPSC Market, by Application

6.1. Key Findings

6.2. Introduction

6.2.1. Global iPSC Market, by Application, 2017 - 2028 (USD Million)

6.3. Manufacturing

6.4. Academic Research

6.5. Drug Development & Discovery

6.6. Toxicity Screening

6.7. Regenerative Medicine

7. Global iPSC Market, by Geography

7.1. Key findings

7.2. Introduction

7.2.1. iPSC Market Assessment, By Geography, 2017 - 2028 (USD Million)

8. Competitive Landscape

8.1. Expansion and Acquisition Analysis

8.1.1. Expansion

8.1.2. Acquisitions

8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

9.1. Company Overview

9.2. Financial Performance

9.3. Product Benchmarking

9.4. Recent Development

For more information about this report visit https://www.researchandmarkets.com/r/ykewbe

See more here:
Global Induced Pluripotent Stem Cell (iPSC) Market Report 2021-2028 - Increasing Demand for Body Reconstruction Procedures and Tissue Engineering -...